Successful Treatment of Late, Recurrent Wilms Tumor With High-dose Chemotherapy and Autologous Stem Cell Rescue in Third Complete Response

2010 ◽  
Vol 32 (6) ◽  
pp. e241-e243 ◽  
Author(s):  
Evangeline Brown ◽  
Andre Hebra ◽  
Joseph Jenrette ◽  
Michelle Hudspeth
Keyword(s):  
Stem Cell ◽  
Successful Treatment ◽  
Wilms Tumor ◽  
Complete Response ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors

2004 ◽  
Vol 22 (10) ◽  
pp. 1934-1943 ◽  
Author(s):  
Shakeel Modak ◽  
Sharon Gardner ◽  
Ira J. Dunkel ◽  
Casilda Balmaceda ◽  
Marc K. Rosenblum ◽  
...  
Keyword(s):  
Stem Cell ◽  
Germ Cell ◽  
Median Survival ◽  
Germ Cell Tumors ◽  
Complete Response ◽  
High Dose Chemotherapy ◽  
Entire Group ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

Purpose To evaluate the efficacy and toxicity of high-dose chemotherapy (HDC) followed by autologous stem-cell rescue (ASCR) in patients with relapsed or progressive CNS germ cell tumors (GCTs). Patients and Methods Twenty-one patients with CNS GCTs who experienced relapse or progression despite having received initial chemotherapy and/or radiotherapy were treated with thiotepa-based HDC regimens followed by ASCR. Results Estimated overall survival (OS) and event-free survival (EFS) rates for the entire group 4 years after HDC were 57% ± 12% and 52% ± 14%, respectively. Seven of nine (78%) patients with germinoma survived disease-free after HDC with a median survival of 48 months. One patient died as a result of progressive disease (PD) 39 months after HDC, and another died as a result of pulmonary fibrosis unrelated to HDC 78 months after ASCR without assessable disease. However, only four of 12 patients (33%) with nongerminomatous germ cell tumors (NGGCTs) survived without evidence of disease, with a median survival of 35 months. Eight patients with NGGCTs died as a result of PD, with a median survival of 4 months after HDC (range, 2 to 17 months). Patients with germinoma fared better than those with NGGCTs (P = .016 and .014 for OS and EFS, respectively). Patients with complete response to HDC also had significantly better outcome (P < .001 for OS and EFS) compared with patients with only a partial response or stable disease. There were no toxic deaths because of HDC. Conclusion Dose escalation of chemotherapy followed by ASCR is effective therapy for patients with recurrent CNS germinomas and might be effective in patients with recurrent NGGCTs with a low tumor burden.

High-dose chemotherapy with autologous stem cell rescue in breast cancer

1996 ◽  
Vol 37 (3) ◽  
pp. 277-289 ◽  
Author(s):  
Robert O. Dillman ◽  
Neil M. Barth ◽  
Shankar K. Nayak ◽  
Cristina DeLeon ◽  
Audrey O'Connor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

High‐dose chemotherapy followed by autologous stem cell rescue in Wilms tumors: French report on toxicity and efficacy

2021 ◽  
Author(s):  
Manon Delafoy ◽  
Arnauld Verschuur ◽  
Gudrun Scheleirmacher ◽  
Marie‐Dominique Tabone ◽  
Hélène Sudour‐Bonnange ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

scholarly journals Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma

2007 ◽  
Vol 40 (1) ◽  
pp. 37-45 ◽  
Author(s):  
K W Sung ◽  
S H Lee ◽  
K H Yoo ◽  
H L Jung ◽  
E J Cho ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Stage 4 ◽  
Autologous Stem Cell Rescue
Sign in / Sign up

Export Citation Format

Share Document